Current Market Cap $224.2m

Management Bio's

Jim McLean

James (Jim) McLean is the Chair of the Board of Directors of Aroa Biosurgery.He is a resident of New Zealand and has been a Director of Aroa Biosurgery since August 2011. For 25 years he has served as either Chair, Director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to Aroa Biosurgery, Jim is also Chair of Prevar Limited. Jim was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through public listing.Before specialising in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years’ secondment to EY’s Washington DC office. Jim has a BSc (Hons) in Chemistry from University of Otago and a Post Graduate Diploma in Accounting from Victoria University of Wellington. Jim is considered by the Board to be an independent Director and is a member of the Audit and Risk Committee and Remuneration and Nomination Committee.

Brian Ward

Brian is the Founder and Chief Executive Officer of Aroa Biosurgery. He is a resident of New Zealand and has been a director of Aroa Biosurgery since September 2007. He has held senior corporate roles in life sciences and health care companies over the last 25 years. He has extensive management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on a number of government and industry expert panels. Brian has been responsible for leading the Company’s growth from start-up through to becoming a vertically integrated medical device business with substantial US sales and a developing international presence.He is a graduate from Massey University with a Bachelor’s degree in Veterinary Science, a Member of the Royal College of Veterinary Surgeons (UK), and holds a Masters degree in Business Administration graduating with distinction. Brian is the managing director and chief executive officer of the Company and a substantial shareholder in the Company and as such he is considered by the Board to not be an independent Director.

Catherine Mohr

Catherine is a Non-Executive Director of Aroa Biosurgery. She is a New Zealand citizen and resident of the United States and has been a director of Aroa Biosurgery since November 2022. Catherine’s diverse background spans several areas, including surgery, medical technology, engineering, product development and design, intellectual property, U.S Food & Drug Administration compliance and education, global entrepreneurship, automotive and aerospace. Currently, Catherine is the President of the Intuitive Foundation, the corporate Foundation of Silicon Valley based Intuitive Surgical, pioneers in the field of robotic-assisted surgery and maker of the da Vinci surgical robot system. Prior to leading the Foundation, Catherine held several senior roles at Intuitive Surgical, including Vice President of Strategy and Director of Medical Research. Catherine is on the board of directors for FINCA International and has been involved with several successful emerging companies in medical technology and other areas, notably co-founding VeriSure, where she invented the LapCap™, the first of a new category of laparoscopic surgery enabling products.Catherine holds a Bachelor of Science and Master of Science in Mechanical Engineering from Massachusetts Institute of Technology (MIT), and a Doctor of Medicine from the Stanford University School of Medicine.

Phil McCaw

Philip (Phil) McCaw is a Non-Executive Director of Aroa Biosurgery. He is a resident of New Zealand, is the Founding Partner of Movac, one of New Zealand’s leading venture capital funds. He led the original investment round into AROA in 2008 and has worked closely with the Company and has served on the Board since then. He is currently the Executive Chair and CEO of Author-IT Software Corporation, a software company that delivers component authoring solutions, enabled by AI, for the largest global pharmaceutical companies. He was also Chair of the New Zealand Government’s Startup Advisors’ Council, established to help identify and address the opportunities and challenges facing high growth start-up businesses. Phil has over 20 years’ experience investing into New Zealand technology companies and helping to guide their growth. He was an early investor in Trade Me, New Zealand’s leading on-line trading community, which was sold to Fairfax in 2006. Phil was also an early investor into PowerByProxi, a wireless power technology spin-out John Pinion Outside of Movac, Phil remains an active angel investor and maintains a personal angel investment portfolio. He is a strong advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand. Prior to starting Movac, Phil spent 10 years with Deloitte Consulting working in New Zealand and the US. As a substantial shareholder in AROA, Phil is considered by the Board to not be an independent director. Phil has a Bachelor of Business Studies (Senior Scholar) from Massey University.

Paul Shearer

Paul is a Non-Executive Director of Aroa Biosurgery. He is a resident of New Zealand and joined AROA’s Board in October 2025. Paul is an accomplished global healthcare executive with extensive experience in the medical device industry and a proven record of leading international sales growth. Paul’s most recent role was as Senior Vice President – Sales & Marketing at Fisher & Paykel Healthcare, which he held for over 20 years. Before joining Fisher & Paykel Healthcare, Paul held roles at ICL Limited and Computercorp Limited. Paul is a current director of Skellerup Holdings, a New Zealand manufacturer and global exporter of rubber and polymer products. Paul holds a Bachelor of Commerce (Marketing) from the University of Canterbury.

Darla Hutton

Darla is a Non- Executive Director of Aroa Biosurgery, She is a resident of the United States and has been a director of Aroa Biosurgery since March 2024. She has more than 25 years of medical technology experience, including global leadership expertise in commercial strategy, operations, sales, marketing, healthcare analytics, lean and enterprise consulting. Darla is currently Vice President, Asia Commercial Operations and Marketing at Intuitive, pioneers in the field of robotic-assisted surgery and maker of the da Vinci surgical and ION diagnostic robot systems. Throughout her tenure at Intuitive, Darla has held commercial roles of increasing responsibility including Regional Sales Director, Vice President of Corporate Accounts-US, and Vice President Marketing, Market Access & Custom Hospital Analytics. In these roles, she has contributed to the expansion of Intuitive’s commercial operations capabilities and range of global offerings. In addition, Darla has served as a member of Intuitive’s Inclusion and Diversity Executive Council. Prior to Intuitive, Darla held commercial positions at other successful medical technology, pharmaceutical, and biotech companies, including Boston Scientific and GlaxoSmithKline, and spent her early professional career in the cardiac-thoracic nursing field. Darla holds a Bachelor of Science and Master of Science from the University of Tampa.

John F Diddams

John is a Non-Executive Director of Aroa Biosurgery. He is a resident of Australia and joined the Board in November 2019. John has over forty years’ experience as a CFO, CEO and director of both private and publicly listed companies. John has extensive knowledge and experience in the practical application of ASX Listing Rules, Australian corporations’ law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in a number of diverse industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors. John holds a Bachelor of Commerce from University of NSW, is a Fellow of the Australian Society of CPAs and a Fellow of the Australian Institute of Company Directors. John is currently Chairman of the Board of xReality Group Limited (ASX:XRG) as well as a non-executive director of New Zealand based Volpara Health Technologies Limited (ASX:VHT), Surf Lakes Holdings Limited and DIT AgTech Limited. John is considered by the Board to be an independent Director and is Chair of the Audit and Risk Committee.